While still robust, CSL half-year results last Weds revealed impact of an “alarming” fall off in 'flu vax rates, especially ...

CSL has received approval from the European Commission (EC) for Andembry (garadacimab) to prevent recurrent attacks of ...

CSL has been given approval by the European Commission for Andembry, the first once-monthly preventive therapy for the ...

The European Commission (EC) has approved CSL’s Andembry (garadacimab) to prevent attacks of hereditary angioedema (HAE) in ...

The European Commission (EC) has approved Andembry (garadacimab), the first and only once-monthly treatment targeting factor XIIa to prevent attacks of hereditary angioedema (HAE) in adult and ...

Global biotechnology leader CSL has announced that the European Commission (EC) has approved ANDEMBRY (garadacimab), the ...

Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) today announced that the European Commission (EC) has approved ...

CEO Paul McKenzie announced a reaffirmation of guidance for fiscal 2025, targeting NPATA growth of 10% to 13%. He highlighted strong results from CSL Behring and growth in CSL Vifor, while ...

CSL (ASX: CSL) shares fell 4.9% on Tuesday following the company’s report of weaker-than-expected first-half revenue, net ...

CSL’s vaccine division is suffering as Americans turn away from flu vaccinations, with a “very severe” influenza season ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved CSL’s Andembry (garadacimab) to prevent angioedema attacks in hereditary angioedema (HAE) patients aged 12 years and older.

Goldman notes that both the Australian Therapeutic Goods Administration (TGA) and the UK's Medicines and Healthcare products Regulatory Agency (MHRA) have approved the registration of ANDEMBRY ...